The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (20 analysts) rates it buy, with a mean price target of $278. It reported earnings in this window, a natural checkpoint for the thesis.
IBM
IBM · a US exchange · USD · Market cap $201.8B · 264,300 employees
International Business Machines Corporation, together with its subsidiaries, provides integrated solutions and services in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
FAIL · Does not pass the screenAt the last full screen
2026-07-24
Screened 2026-07-24 · the tape above runs as of 22:40 UTC · 24 Jul · two dates, stated on purpose · verdict and workings shown in full · never trimmed
This name holds its markup label.
IBM holds its Markup at $214.19. Consolidating, no directional conviction, held for 2 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 2 days |
| Price at the screen | $214.19 |
| Valuation | 19.02 trailing · 16.21 forward price to earnings |
| Values screen | FAIL · score 10.0 |
Five Screens, Shown in Full
Does not pass. Debt ratio
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 42.54% | Below 33% | Interest-bearing debt is 42.5% of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | 0.55% | Below 33% | Cash held in interest-bearing accounts and securities is 0.5% of assets, under the one-third limit. | Pass |
| Receivables | 14.29% | Below 49% | Money owed to the company is 14.3% of assets, under the 49% limit. | Pass |
| Revenue purity | 0.96% | Below 5% | Only 1.0% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Conscience OverlayThe quantitative screen above is arithmetic. Separately, community boycott lists cite this company: Cited by BDS movement for legacy technology contracts and ongoing operations supporting Israeli government infrastructure. The desk records that flag here without folding it into the verdict: the screen measures the balance sheet, the overlay informs the conscience, and they are different judgements that belong to different owners. The second one is yours.
The Fair Value Range
Our framework reads AVOID: it trades at roughly a 19% discount to our $255.45 fair value, moderate competitive moat, 1.10% revenue growth.
Fair value range in USD, drawn from the 2026-07-24 screen. The gold marker is the market price at the same screen. A 19.3% margin of safety to the base estimate.
Third-party analyst targets: 23 covering, consensus Buy. The average target sits +14% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-07-24 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsIBM Trips on Debt Before Any Upside
Think of IBM as the corporate mainframe that still hums away in data centres everywhere. It posts a 36 percent return on equity, 10 percent revenue growth and a 16 percent profit margin, yet we pass without hesitation. The ethical screen flags excessive debt and that alone rules the stock out, margin of safety or not.
Forward earnings sit at 16 times and the moat remains only moderate. Wall Street sees a buy with a 275 dollar median target, but none of those numbers overcome the debt failure. We treat the ethical verdict as final rather than negotiable.
Cyclical IT spending and legacy exposure add further uncertainty around steady cash conversion. Analysis, not advice.
| Forward P/E | 16.2xexpensive even after accounting for its growth |
| Trailing P/E | 19.0xreasonably valued |
| EPS, trailing | 11.26 |
| EPS, forward | 13.21 |
| Revenue growth | +1.1%slow but positive growth |
| Profit margin | 15.5%healthy profit margins |
| Return on equity | 34.5%an exceptional return on shareholder capital |
| FCF yield | 5.89% |
| Dividend yield | 294.00% |
| Debt to equity | 1.89a meaningful debt load worth watching |
| Current ratio | 0.79below 1: short-term bills exceed liquid assets |
| Short interest, float | 0.04% |
| 52-week range | 199.19 - 332.46 |
| Moat | MODERATE |
| Market cap | $201.8B |
| Employees | 264,300 |
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeIBM trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (20 analysts) rates it buy, with a mean price target of $278. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (20 analysts) rates it buy, with a mean price target of $278. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 25.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (20 analysts) rates it buy, with a mean price target of $278. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (20 analysts) rates it buy, with a mean price target of $278. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (20 analysts) rates it buy, with a mean price target of $278. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (20 analysts) rates it buy, with a mean price target of $278. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- ORCL Has Left Its Peers Behind. Or Has It? Trefis · 1d ago
- Quantum Is Coming for Crypto. Wall Street Is Spending Millions to Stop It. Barrons.com · 1d ago
- ServiceNow’s quiet $1B cybersecurity boom TheStreet · 1d ago
- Nvidia, Microsoft and other tech giants back open-source AI models Reuters · 1d ago
- Why Meta, Microsoft, and Nvidia are championing open-weight AI Investing.com · 2d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-25 | HOWARD MICHELLE J. | Director | 50 | $11,891 | |
| 2026-02-25 | MIEBACH MICHAEL | Director | 434 | $101,264 | |
| 2026-02-20 | LAMOREAUX NICKLE JACLYN | Officer | 4,391 | · | |
| 2026-02-20 | FEHRING NICOLAS A. | Officer | 1,568 | · | |
| 2026-02-20 | THOMAS ROBERT DAVID | Officer | 8,414 | · | |
| 2026-02-20 | KAVANAUGH JAMES J. | Chief Financial Officer | 9,832 | · | |
| 2026-02-20 | KRISHNA ARVIND | Chief Executive Officer | 16,903 | · | |
| 2026-02-20 | COHN GARY D | Officer | 7,582 | · | |
| 2026-02-18 | LAMOREAUX NICKLE JACLYN | Officer | 1,586 | · | |
| 2026-02-18 | FEHRING NICOLAS A. | Officer | 696 | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 24 Apr2026 | Josh Gottheimer | Democrat | sell | 1K–15K |
| 2026-04-24 | Josh Gottheimer | Democrat | Sale | 1K–15K |
| 2026-04-24 | Ro Khanna | Democrat | Purchase | 15K–50K |
| 2026-04-13 | Ro Khanna | Democrat | Purchase | 1K–15K |
| 16 Jun2026 | Gil Cisneros | Democrat | buy | 15K–50K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $223.55 | +22.2% | · | $1,222 | +22.2% |
| 2 months | $229.07 | +19.2% | $1.69 | $1,200 | +20.0% |
| 3 months | $245.87 | +11.1% | $1.69 | $1,118 | +11.8% |
| 6 months | $306.72 | -11.0% | $3.37 | $901 | -9.9% |
| 1 year | $269.35 | +1.4% | $6.73 | $1,039 | +3.9% |
| 2 years | $161.25 | +69.4% | $13.42 | $1,777 | +77.7% |
| 3 years | $122.82 | +122.4% | $20.07 | $2,387 | +138.7% |
| 5 years | $118.93 | +129.6% | $33.18 | $2,575 | +157.5% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever IBM does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.